/IL-6R Pathway As a Potential Therapeutic Target for Ovarian High-grade Serous Carcinoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2019 Aug 27

PMID 31448054

Citations 3

Authors

Ryo Yokomizo

Nozomu Yanaihara

Noriko Yamaguchi

Misato Saito

Ayako Kawabata

Kazuaki Takahashi

Masataka Takenaka

Kyosuke Yamada

Jason Solomon Shapiro

Aikou Okamoto

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence has indicated that microRNAs play a critical role in the pathogenesis of human cancers. () has been shown to be a key regulator of tumor suppression by targeting several cancer-related signals, including the interleukin-6 receptor (IL-6R)/Signal Transducers and Activator of Transcription 3 (STAT3) signaling pathway. Previously, we determined that expression was frequently reduced in high-grade serous carcinoma (HGSC), the major subtype of epithelial ovarian cancer (EOC). Considering that the IL-6R/STAT3 signaling pathway is upregulated and believed to be a potential therapeutic target in EOC, we investigated the biological significance of reduced expression in HGSC with regard to IL-6R signaling. Additionally, we evaluated the viability of as a therapeutic application for HGSC both and . Accordingly, we found that the ectopic expression of significantly reduced tumor proliferation and invasion through downregulation of IL-6R expression, suggesting that reduced expression might play an important role in the malignant potential of HGSC through upregulation of the IL-6R/STAT3 signaling pathway. Moreover, we demonstrated that replacement of reduced tumorigenicity of HGSC . Therefore, this study may provide the rationale for replacement as a promising therapeutic strategy for HGSC.

Citing Articles

Interleukin-6 Modulation in Ovarian Cancer Necessitates a Targeted Strategy: From the Approved to Emerging Therapies.

Amer H, Kampan N, Itsiopoulos C, Flanagan K, Scott C, Kartikasari A Cancers (Basel). 2025; 16(24.

PMID: 39766086 PMC: 11674514. DOI: 10.3390/cancers16244187.

Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway.

Iida Y, Yanaihara N, Yoshino Y, Saito M, Saito R, Tabata J Front Oncol. 2024; 14:1302850.

PMID: 38420012 PMC: 10899666. DOI: 10.3389/fonc.2024.1302850.

Novel Insights into Epigenetic Regulation of IL6 Pathway: In Silico Perspective on Inflammation and Cancer Relationship.

Candido S, Tomasello B, Lavoro A, Falzone L, Gattuso G, Libra M Int J Mol Sci. 2021; 22(18).

PMID: 34576335 PMC: 8470126. DOI: 10.3390/ijms221810172.

MicroRNA-34a deficiency leads to impaired wound closure by augmented inflammation in mice.

Zhao N, Wang G, Long S, Hu M, Gao J, Ran X Ann Transl Med. 2020; 8(7):447.

PMID: 32395491 PMC: 7210195. DOI: 10.21037/atm.2020.03.161.

References

Yamamoto K, Kikuchi Y, Kudoh K, Nagata I . Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol. 2000; 126(3):168-72. DOI: 10.1007/s004320050027. View

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y . Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005; 11(16):6030-9. DOI: 10.1158/1078-0432.CCR-04-2671. View

Nilsson M, Langley R, Fidler I . Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005; 65(23):10794-800. PMC: 1534114. DOI: 10.1158/0008-5472.CAN-05-0623. View

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

Calin G, Croce C . MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006; 66(15):7390-4. DOI: 10.1158/0008-5472.CAN-06-0800. View

Su H, Yeh H, Wang S, Shen M, Chen T, Kiela P . Cell confluence-induced activation of signal transducer and activator of transcription-3 (Stat3) triggers epithelial dome formation via augmentation of sodium hydrogen exchanger-3 (NHE3) expression. J Biol Chem. 2007; 282(13):9883-9894. DOI: 10.1074/jbc.M606754200. View

Corney D, Hwang C, Matoso A, Vogt M, Flesken-Nikitin A, Godwin A . Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010; 16(4):1119-28. PMC: 2822884. DOI: 10.1158/1078-0432.CCR-09-2642. View

Wang Y, Niu X, Qu Y, Wu J, Zhu Y, Sun W . Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010; 295(1):110-23. DOI: 10.1016/j.canlet.2010.02.019. View

Rath K, Funk H, Bowling M, Richards W, Drew A . Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am J Obstet Gynecol. 2010; 203(3):230.e1-8. DOI: 10.1016/j.ajog.2010.03.034. View

10.

Guo Y, Nemeth J, OBrien C, Susa M, Liu X, Zhang Z . Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res. 2010; 16(23):5759-69. DOI: 10.1158/1078-0432.CCR-10-1095. View

11.

Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M . Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene. 2011; 30(38):4038-49. DOI: 10.1038/onc.2011.119. View

12.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

13.

Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster D . Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011; 17(18):6083-96. PMC: 3182554. DOI: 10.1158/1078-0432.CCR-11-0945. View

14.

Hutchins A, Poulain S, Miranda-Saavedra D . Genome-wide analysis of STAT3 binding in vivo predicts effectors of the anti-inflammatory response in macrophages. Blood. 2012; 119(13):e110-9. DOI: 10.1182/blood-2011-09-381483. View

15.

Yanaihara N, Anglesio M, Ochiai K, Hirata Y, Saito M, Nagata C . Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol. 2012; 41(3):1094-100. DOI: 10.3892/ijo.2012.1533. View

16.

Hermeking H . MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012; 12(9):613-26. DOI: 10.1038/nrc3318. View

17.

Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot C . Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013; 23(2):186-99. PMC: 3603369. DOI: 10.1016/j.ccr.2012.12.020. View

18.

Rebe C, Vegran F, Berger H, Ghiringhelli F . STAT3 activation: A key factor in tumor immunoescape. JAKSTAT. 2013; 2(1):e23010. PMC: 3670267. DOI: 10.4161/jkst.23010. View

19.

Rokavec M, Oner M, Li H, Jackstadt R, Jiang L, Lodygin D . IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014; 124(4):1853-67. PMC: 3973098. DOI: 10.1172/JCI73531. View

20.

Davidson B, Trope C, Reich R . The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecol Oncol. 2014; 133(3):640-6. DOI: 10.1016/j.ygyno.2014.03.575. View